Thirty Years of Progress Thanks to the RET Oncogene
Mené sur 291 patients atteints d'un cancer médullaire de la thyroïde présentant une mutation au niveau du gène RET et de stade avancé (durée médiane de suivi : 12 mois), cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du selpercatinib (un inhibiteur de RET) et d'un traitement de première ligne choisi par le médecin (cabozantinib ou vandétanib)
Although medullary thyroid cancer accounts for less than 5% of thyroid cancers, it deserves attention because of its phenotypic heterogeneity, its often aggressive behavior, and the long-term lack of curative postoperative treatment. In 25% of cases, medullary thyroid cancer may be part of a rare genetic tumor syndrome, multiple endocrine neoplasia type 2 (MEN-2). In 1993, mutations in the RET (rearranged during transfection) proto-oncogene were identified by Mulligan and colleagues as responsible for MEN-2.1 It is therefore quite a coincidence that on the 30th anniversary of the discovery of RET, the first drug specifically targeting this pathway is now recognized (...)